ERNA — Ernexa Therapeutics Inc. Dilution Risk Tracker

Ernexa Therapeutics Inc. (ERNA) carries a DilutionScore of 99/100, placing it in the Critical dilution risk tier — the highest category tracked by DilutionWatch. Companies at this level typically have active capital-raising programs, compressed cash runway, or a combination of dilution vectors that together represent meaningful downside risk to share count. As of July 13, 2026, this score reflects real-time data pulled directly from SEC EDGAR filings.

The most significant dilution vector for ERNA is its shelf registration capacity of $50.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely. ERNA has an active ATM (at-the-market) program with $10.0M remaining capacity. ATM programs allow companies to sell shares continuously into the open market through a broker-dealer — without announcing a secondary offering. This creates a silent but steady source of share dilution that shows up in quarterly share count increases rather than a discrete offering event.

DilutionWatch tracks over 25 SEC filing types for ERNA in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for ERNA alongside comparable critical-risk stocks. Not financial advice — this analysis is for informational purposes only.